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Abstract
Background: Estradiol has been shown to exert neuroprotective effects in several neurodegenerative conditions,
including cerebral ischemia. The presence of this hormone prior to ischemia attenuates the damage associated
with such events in a rodent model (middle cerebral artery occlusion (MCAO)), although its therapeutic value when
administered post-ischemia has not been assessed. Hence, we evaluated the effects of estradiol treatment after
permanent MCAO (pMCAO) was induced in rats, studying the PI3K/AKT/GSK3/β-catenin survival pathway and the
activation of SAPK-JNK in two brain areas differently affected by pMCAO: the cortex and hippocampus. In addition,
we analyzed the effect of estradiol on the glial response to injury.
Methods: Male rats were subjected to pMCAO and estradiol (0.04 mg/kg) was administered 6, 24, and 48 h after
surgery. The animals were sacrificed 6 h after the last treatment, and brain damage was evaluated by
immunohistochemical quantification of ‘reactive gliosis’ using antibodies against GFAP and Iba1. In addition, Akt,
phospho-AktSer473, phospho-AktThr308, GSK3, phospho-GSK3Ser21/9, β-catenin, SAPK-JNK, and pSAPK-JNKThr183/Tyr185
levels were determined in western blots of the ipsilateral cerebral cortex and hippocampus, and regional
differences in neuronal phospho-Akt expression were determined by immunohistochemistry.
Results: The increases in the percentage of GFAP- (5.25-fold) and Iba1- (1.8-fold) labeled cells in the cortex and
hippocampus indicate that pMCAO induced ‘reactive gliosis’. This effect was prevented by post-ischemic estradiol
treatment; diminished the number of these cells to those comparable with control animals. pMCAO down-
regulated the PI3K/AkT/GSK3/β-catenin survival pathway to different extents in the cortex and hippocampus, the
activity of which was restored by estradiol treatment more efficiently in the cerebral cortex (the most affected
region) than in the hippocampus. No changes in the phosphorylation of SAPK-JNK were observed 54 h after
inducing pMCAO, whereas pMCAO did significantly decrease the phospho-AktSer473 in neurons, an effect that was
reversed by estradiol.
Conclusion: The present study demonstrates that post-pMCAO estradiol treatment attenuates ischemic injury in
both neurons and glia, events in which the PI3K/AKT/GSK3/β-catenin pathway is at least partly involved. These
findings indicate that estradiol is a potentially useful treatment to enhance recovery after human ischemic stroke.
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Introduction
Ischemic stroke is a highly disabling neurodegenerative
condition with a high incidence in industrialized coun-
tries [1]. Ischemic strokes in humans account for
approximately 80% of all strokes [1] and they are caused
by thrombotic or embolic occlusion that decreases or
suppresses the flow of blood in the middle cerebral
artery (MCA), one of the main arteries supplying blood
to the brain [2]. Brain injury following cerebral ischemia
involves a complex succession of events that evolve
spatially and temporally, causing varying degrees of cell
damage depending on the characteristics of the initial
insult [3]. The ischemic core and the peri-infarct zone
(penumbra) suffer differing degrees of cellular damage
[3-5], and it is widely accepted that cell death in the
ischemic core is triggered by necrosis while that which
occurs in the penumbra is predominantly mediated by
apoptosis [4]. As apoptosis is a reversible process, thera-
peutic interventions targeting this process have the poten-
tial to prevent or limit cell death in the peri-infarct zone,
even when applied post-ischemia.
MCA occlusion (MCAO) is a rodent model of ische-
mia that is widely used to analyze the mechanisms
triggered by ischemic stroke and to study potential treat-
ments. In this model, the cerebral cortex and the stri-
atum are most affected brain regions, while secondary cell
death occurs in the hippocampus [6]. Two types of
MCAO stroke models are commonly used: transient
ischemia (tMCAO) with reperfusion and permanent
ischemia (pMCAO) without reperfusion. The latter is
more similar to naturally occurring cerebral ischemia in
humans and, thus, it is of greater clinical relevance [5].
Moreover, this model provides a useful means to test
therapeutic approaches aimed at repairing the injured
tissue in the late stages of cerebral ischemia [4].
Estradiol is the main female sex hormone that, in
addition to its classic role in reproduction, exerts po-
tent neurotrophic and neuroprotective effects in the
brain [7]. Strokes naturally occur less in females than in
age-matched males up to the age of 75 years, after
which the incidence in women increases [8,9]. A large
body of evidences suggests that estradiol protects
against brain injury and several neurodegenerative
diseases [10]. Indeed, physiological [11,12] or pharma-
cological levels [13] of estradiol administered prior to
tMCAO or pMCAO [11,14-16] reduce the area of
ischemic damage in rodent models of stroke [16-19].
While few studies have investigated the effects of post-
pMCAO estradiol administration, it appears to exert a
protective effect if administered within a therapeutic
window of approximately 3 h post-ischemia [13,20].
However, deleterious effects of estradiol have also been
described under certain conditions, possibly related to the
estradiol dose or the severity and duration of ischemia,
[21,22]. Moreover, some studies have demonstrated that
the neuroprotective effect of estradiol is not equal in all
areas affected by MCAO and that it appears to be con-
fined to the cerebral cortex, with no detectable benefit in
the striatum [10].
Three possible mechanisms have proposed for the
neuroprotective effects of estrogen: (1) antioxidant
effects; (2) regulation of gene transcription after binding
to its classical receptor (ERα or ERβ); and (3) activation
of different membrane-associated intracellular signaling
pathways [10,23]. Indeed, interaction of estradiol and
IGF-1 has been shown to promote neuroprotection. ERα
can physically interact with downstream signaling mole-
cules of the phosphatidylinositol 3-kinase (PI3K)/Akt/
glycogen synthase kinase 3 (GSK3) pathway in an
estrogen-dependent manner [23-25]. Moreover, we re-
cently demonstrated that ERα is linked to PI3K-
associated cytoplasmic signaling, and that estradiol can
activate Akt/PKB and subsequently inhibit glycogen syn-
thase kinase 3 (GSK3) [26], which may constitute a
mechanism to promote neuronal survival [27]. While
several studies have implicated the PI3K/Akt/GSK3
pathway in cell death after transient [28-30] or permanent
[31] cerebral ischemia, it remains unclear whether modifi-
cation of this pathway after pMCAO can ameliorate the
effects of ischemic damage.
Mitogen-activated protein kinases (MAPKs) are
divided in three families: extracellular signal regulated
kinases (ERKs), c-Jun-N-terminal kinases (JNKs), and
p38 MAPKs, each of which play crucial roles in signal
transduction and regulate cell death and survival.
MAPKs are strongly expressed in the central nervous
system, and several studies have reported that alterations
in MAPK expression and/or activation in post-ischemic
brain tissues can affect the outcome of ischemic brain
injury in animal models [32]. JNK and p38 are activated
by exposing cells to stress and/or inflammatory cyto-
kines [33]. Phosphorylation of JNK is associated with
apoptosis [34], although the specific effects of JNK are
highly dependent on the cell type and experimental
setting [32]. Immediate activation of all three MAPKs
has been described in neurons and glia in a mouse
model of permanent ischemia [35], and extended activa-
tion for up to 1 day has been described for ERK and p38
[36]. The role of p-JNK, the active form of JNK, in cerebral
ischemia is unclear, and the few studies that have ana-
lyzed the distribution of activated JNK following
pMCAO suggest a role in neuronal apoptosis and in
the angiogenic response to cerebral ischemia [37,38].
Treatment with JNK inhibitors effectively reduces the
infarct volume 48 h after tMCAO in mice [39]. Further-
more, activation of the PI3K-Akt pathway in cerebellar
granule neurons has been proposed to prevent neuronal
cell death by suppressing JNK activation [40].
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In the present study, we evaluated the impact of post-
ischemic estradiol treatment in rats on the late stages of
cerebral ischemia (54 h post-pMCAO), analyzing the ac-
tivation of the PI3K/Akt/GSK3/β-catenin pathway and
of SAPK-JNK in two brain areas affected by pMCAO:
the cerebral cortex and the hippocampus. Our results in-
dicate that estradiol treatment reduces the build-up of
gliotic tissue triggered by pMCAO. Moreover, estradiol
treatment reversed the down-regulation of the PI3K/
Akt/GSK3/β-catenin pathway induced by pMCAO in
the cortex, and to a lesser extent, in the ipsilateral
hippocampus. Finally, pMCAO had no effect on the acti-
vation status of SAPK-JNK in both the cerebral cortex
and hippocampus, as reflected by its phosphorylation,
although post-pMCAO estradiol treatment decreases
SAPK-JNK phosphorylation in both these areas, only sig-
nificantly in the hippocampus.
Materials and methods
Animals
Experiments were performed on adult male Wistar rats
(8–12 weeks old, 250–310 g) obtained from the vivarium
at the CBM-SO. Animals were housed in a room with
controlled temperature and relative humidity on an alter-
nating 12/12 h light/dark cycle, and they were given ad
libitum access to food and water. Animal care protocols
conformed to the appropriate national legislations (de-
cree 1201/2005, BOE no. 252) and the guidelines of the
Council of European Communities (86/609/CEE).
Induction of focal cerebral ischemia
Permanent focal cerebral ischemia was induced by
occluding the middle cerebral artery using the previously
described intraluminal suture method [41], with minor
modifications. Rats were anesthetized with an intraperi-
toneal injection of a mixture of medetomidine (250 μg/
kg) and ketamine (75 mg/kg), accompanied by a sub-
cutaneous injection of atropine (100 μg/kg). The right
common carotid artery (CCA) was exposed and dis-
sected, and the right external carotid artery (ECA) and
right internal carotid artery (ICA) were isolated. The
first artery branches of the ECA and the pterygopalatine
artery were electro-cauterized using a High Temperature
Cautery Power Handle (Aaron Medical, Clearwater,
USA). To occlude the origins of the MCA, a 4–0 mono-
filament Dafilon nylon suture (B/Braun, Aesculap AG
Et. Co., Tuttlingen, Germany), the tip of which was
rounded by heating and that was coated with poly-L-
lysine (0.1% wt/vol in deionized water; Sigma, St Louis,
MO, USA), was introduced into the ECA lumen and
advanced into the ICA lumen until it met mild resistance,
approximately 2.2 cm beyond the CCA bifurcation. The
suture was secured with a ligature and was maintained in
place until sacrifice. Sham operated rats were subjected to
identical surgical procedures but no suture was inserted.
Neurological deficit score
The neurological deficit score of each rat was measured
before surgery, and 6 h after pMCAO induction, just be-
fore administration of the first estradiol dose, using a
slightly modified version of the method described by
Yrjänheikki [42]. To determine whether ischemia was
induced correctly, the assessment was performed by an
individual who was blind to the experimental treatment
groups. A six-point scale of neuromotor function was
graded as follows: Grade 5, normal extension of both
forelimbs towards the floor when lifted; Grade 4, con-
sistently reduced resistance to a lateral push towards the
paretic side; Grade 3, circling towards the paretic side
when pulled and lifted by the tail; Grade 2, circling to-
wards the paretic side when pulled by the tail; Grade 1,
spontaneous circling towards the paretic side; Grade 0:
no spontaneous motion. Other neurological abnormal-
ities were also recorded, such as alterations in balance,
sensorial perception (acoustic, visual localization) and
reflex responses (corneal, palpebral, postural correction).
Estradiol administration
A total of 46 male rats were randomly distributed into
the following experimental groups: sham vehicle (SV,
n = 12), ischemia vehicle (IV, n = 12), sham estradiol (SE,
n = 10), and ischemia estradiol (IE, n = 12). Groups SE
and IE groups received three doses of 0.04 mg/kg β-
estradiol (Sigma, St Louis, MO, USA, ref E8875) in a
total volume of 500 μL, delivered by intra-peritoneal in-
jection 6, 24, and 48 h after pMCAO induction. Groups
IV and SV received 500 μL of the vehicle alone (1% etha-
nol in saline). All animals were sacrificed 6 h after the
last treatment.
Western blotting
Animals were sacrificed by exposure to CO2, decapitated
and their brains were removed quickly. The right cerebral
cortex (ischemic core) and right hippocampus (penumbral
area) were dissected out and frozen at −80 °C for subse-
quent analysis. Tissue samples were homogenized with a
Teflon-glass homogenizer in ice-cold lysis buffer containing:
20 mM Hepes [pH 7.4], 100 mM NaCl, 100 mM NaF,
5 mM EDTA, 1% Triton X-100, 1 mM Na3VO4, and a pro-
tease inhibitor cocktail (Roche Applied Science, Mannheim,
Germany). Samples were kept on ice for 30 min and the in-
soluble material was then removed by centrifugation at
12,000 x g for 15 min. The pellet was discarded and the
supernatants were analyzed in western blots. The protein
concentration of each sample was determined using the
DC Protein Assay kit (BioRad, Hercules, CA, USA)
according to the manufacturer’s instructions. The proteins
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were resolved by SDS-PAGE (8%) using a Mini-Protean
system (Bio-Rad) and depending on the epitope to be
analyzed, 30–50 μg of total protein was loaded into each
lane in loading buffer containing: 0.062 M Tris (pH 6.8),
10% glycerol, 5% β-mercaptoethanol, 7.5 mM EDTA, 2%
SDS, and 0.002% bromophenol blue. Samples were heated
at 100 °C for 3 min before loading. After electrophoresis
the proteins were electrotransferred onto nitrocellulose
membranes (Whatman, Dassel, Germany) for 1.5 h at
100 mV using an electrophoretic transfer system (Mini-
Trans-blot Electrophoretic Transfer Cell). Subsequently,
the membranes were blocked for 1 h with 5% non-fat
powdered milk in phosphate buffered saline (PBS) con-
taining 0.1% Tween-20 (PBS-T) and then they were incu-
bated overnight at 4 °C with the appropriate primary
antibody: Akt (1:1,000; Cell Signaling no. 9272); phospho-
AktSer473 (1:500; Cell Signaling no. 9271), phospho-
AktThr308 (1:1,000; clone C31E5E, Cell Signaling no. 2965),
β-catenin (1:800; BD Transduction Laboratories no.
610153), β-tubulin (1:1,000; clone TUB 2.1, Sigma no.
T4026), β-actin (1:1,000; clone AC-15, Sigma no. A5441),
GSK3 (1:1,000; Biosource no. 44–610), phospho-GSK3Ser21/9
(1:1,000; Cell Signaling no. 9331), SAPK-JNK (1:1,000; Cell
Signaling no. 9252), pSAPK-JNKThr183/Tyr185 (1:1,000; Cell
Signaling no. 9251). The membranes were washed with
PBS-T and incubated for 1 h at room temperature with
the corresponding secondary antibodies: peroxidase-
conjugated goat anti-mouse IgG (H+ L, 1:1,000;
Thermo Scientific no. 32430) or goat anti-rabbit IgG-
HRP (1:5,000; Santa Cruz Biotechnology no. sc-2004).
Specific antibody binding was revealed using the Western
Lightning-ECL chemiluminiscence system (PerkinElmer,
Waltham, MA, USA), according to the manufacturer’s
recommendations. Autoradiography was performed on
AGFA RP2 plus films, using different exposure times
depending on the primary antibody used. The films
were analyzed using Quantity One software, version
4.6.0 (Bio-Rad; U-Max Powerlook 2100 XL scanner) and
the results from each membrane were normalized to the
β-tubulin or β-actin levels detected in the same mem-
brane, and compared with control values (vehicle-treated
sham rats). Samples from all experimental groups were
processed in parallel to minimize inter-assay variation.
The results represent the mean of three to five inde-
pendent experiments.
Tissue collection
Deeply anesthetized animals were transcardially perfused
with ice-cold saline, 54 h after pMCAO induction, fol-
lowed by 4% paraformaldehyde in 0.1 M phosphate
buffer (pH 7.4). The rats’ brains were removed and post-
fixed overnight at 4 °C. The following day, the brains
were washed three times in PBS (15 min each), and cryo-
protected in 30% sucrose in PBS at 4 °C for 48–72 h.
Finally, the brains were embedded in Tissue-Tek medium
(Sakura, Zoeterwoude, NL) and stored at −20 °C. Coronal
cryostat sections (25-μm thick) were obtained from each
brain and three tissue sections were collected onto
each Superfrost Ultra Plus slides (Thermo Scientific,
Braunschweig, Germany), air dried and stored at −20 °C.
Sections located from +2 to −2 relative to bregma were
selected for immunochemistry [43].
Immunohistochemistry
Immunohistochemical analyses were performed in a hu-
midified chamber. The sections were dried at room
temperature for at least 1 h, washed once in PBS
(10 min), permeabilized for 15 min in 0.25% triton X-100
in PBS and incubated for 30 min in blocking solution
containing 0.1% Triton X-100 in PBS supplemented
with 1% horse serum. The slides were incubated over-
night at 4 °C with the appropriate primary antibody
diluted in PBS containing 0.1% Triton X-100 and 1%
horse serum: monoclonal mouse anti-GFAP (1:1,000;
Clon 4A11; BD Pharmigen no. 55632); anti-Iba1 rabbit
(1:500; Wako no. 019–19741); and a monoclonal rabbit
anti-phospho-AktSer473 (1:100; Clon D9E, Cell Signaling
no. 4060). The sections were then washed three times in
PBS containing 0.1% Triton X-100, and again in PBS,
and endogenous peroxidase activity was quenched by
incubating for 30 min in PBS containing 1% hydrogen
peroxide. The slides were subsequently incubated for
1 h at room temperature with the appropriate secondary
antibody: biotin conjugated anti-mouse IgG (diluted
1:200 in PBS containing 1% horse serum) or biotin con-
jugated anti-rabbit IgG (diluted 1:200 in PBS containing
1% normal goat serum). After washing five times with
PBS, the sections were incubated for 30 min with
avidin-biotin-peroxidase complex from the Vector ABC
Elite kit (Vectastain, Vector laboratories Inc., Burligame,
CA, USA). The sections were then washed in PBS and
incubated for 15 min with diaminobenzidine reagent
FAST 3'3 diaminobenzidine tablets (Sigma, D4168). Fol-
lowing dehydration in a series of graded ethanol dilu-
tions (70%, 90%, 100%), the sections were cleared with
xylol and mounted using Entellan New mounting
medium (Electron Microscopy Sciences, Hatfield, PA,
USA). For double immunostaining experiments, follow-
ing incubation with the primary antibody, the sections
were incubated for 1 h with anti-rabbit Alexa 488 and
anti-mouse Alexa 555 fluorescent secondary antibodies
(1:500; Invitrogen). After washing three times with PBS,
the slices were mounted using Fluoromount G (Southern
Biotech). To determine the specificity of the immunoreac-
tions, each batch experiment included control prepara-
tions in which the primary antibody was omitted and the
incubation solution replaced with blocking solution. Slides
immunostained with Iba1 or GFAP were observed under
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an Olympus BX61 microscope and images captured using
an Olympus DP50 camera. Images from slides double-
stained for AktSer473 and GFAP were captured using an
LSM510 laser scanning confocal microscope coupled to
an inverted Axiovert 200 M microscope (Zeiss). The in-
tensity of GFAP and Iba1 immunostaining was quantified
using free image processing software (http://fiji.sc/wiki/
index.php/Fiji).
Statistical analyses
GraphPad Prism software was used for all statistical ana-
lyses and all the data are presented as the mean ± standard
error of the mean (SEM). In all cases, differences were
considered statistically significant where P <0.05. Stu-
dent’s t-test was used to compare differences between
groups. For immunohistochemical data, the positively
stained area was quantified using Fiji image processing
software. The effects of and estrogen treatment on the
area stained positively were compared using the Student’s
t-test.
Results
Neurological status 6 h post-pMCAO
To confirm the induction of ischemic damage, the
neurological capacity was determined in all rats before
and 6 h after inducing pMCAO (Figure 1). Prior to sur-
gery, all the rats attained the maximum score of 5 (data
not shown), whereas at 6 h post-pMCAO, the sham
operated animals attained an IDI score of 4.8 (± 0.3) and
the ischemic rats a score of 2.7 (± 0.3). Thus, pMCAO
had a significant and consistent effect on the neuro-
logical status of the rats (P= 0.00031), confirming their
marked neurological impairment. Ischemic animals that
did not attain a score of 2 to 3 were not included in the
study.
pMCAO induces reactive gliosis in the ischemic tissue, an
effect attenuated by post-ischemic estradiol treatment
Resting glia are activated following brain damage, generating
a stereotypic cellular response known as gliosis, the
timing and extent of which varies depending on the initial
insult [44]. To evaluate the effect of estradiol on reactive
gliosis after pMCAO, we analyzed the accumulation of
astrocytes and microglial cells in coronal sections of the
cortex and hippocampus stained with antibodies against
GFAP or Iba1. GFAP and Iba1 staining were increased in
ischemic tissue, an effect that was more pronounced near
the damaged area (from +2 to −2 relative to bregma).
When quantified and normalized to the total tissue area,
and expressed as a percentage of the damaged area, the
GFAP-positive area was significantly larger in the
pMCAO (IV) group (6.3± 2.1%) than in the corresponding
area (bregma −1.08) of the SV animals (1.2 ± 1.1%,
P = 0.03: Figure 2A). Similarly, the Iba1-positive area
was significantly larger in the pMCAO (IV) rats
(11.55 ± 1.1%) than in the corresponding area of the SV
rats (6.2 ± 0.4%, P = 0.008: Figure 2B). As expected, these
findings demonstrate a marked accumulation of glial
cells (astrocytes and microglia) in the injured tissue
54 h after pMCAO.
Administration of estradiol after p-MCAO reduced
the percentage of GFAP-positive and Iba1-positive area
in damaged tissue, which fell to levels similar to those in
the control animals (SV). These results indicate that
post-pMCAO estradiol treatment can effectively reduce
‘reactive gliosis’ in ischemic tissue (Figure 2).
In the cerebral cortex and hippocampus, pMCAO alters
the activity of the PI3K/akt pathway but not that of JNK
In addition to its genomic action, estrogen rapidly acti-
vates cytoplasmic signaling elements like phosphoinositide
3-kinase (PI3K) [24,45]. We recently demonstrated that
estradiol induces an immediate activation of Akt/PKB,
and the ensuing inhibition of GSK3, in both the mouse
brain and in primary cultures of neurons [26]. Thus, we
investigated the role of the PI3K/Akt pathway in the pro-
tective effect of post-pMCAO estradiol administration.
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Figure 1 The ischemic damage index (IDI) score decreased
significantly 6 h after pMCAO induction in rats. The IDI was
measured using a neurological test, whereby 0 corresponds to the
lowest degree of neurological recovery and 5 the highest. Bar
graphs show the mean neurological score of all the animals studied
6 h after the onset of pMCAO. A marked reduction in the
neurological score was observed in the pMCAO (IV) group when
compared with the SV group (n= 22-24 per group; Student’s t-test,
** P≤ 0.005). The data represent the mean± standard error of the
mean (SEM). SV, Sham-vehicle; IV, pMCAO-vehicle.
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Cell extracts were obtained from the parietal cortical re-
gion and the ipsilateral hippocampus of treated and un-
treated brains, and the functional status of the PI3K
pathway was evaluated with phospho-specific antibodies
targeting activated or inhibited components of this path-
way, as well as antibodies against the total protein. While
no changes in levels of total Akt were detected in the cere-
bral cortex 54 h after the onset of pMCAO (IV group:
Figure 3A), a clear decrease in Akt activity, was evident
when Akt phosphorylation at the Ser-473 and Thr-308
residues was quantified (Figure 3B and 3 C). This reduc-
tion was more pronounced for pAkt Ser-473 (63 ± 8.4%
the SV control levels; P = 0.0001) than for pAkt Thr-308
(46 ± 8.3% the SV control levels; P = 0.03). Post-pMCAO
estradiol administration (IE group) partially recovered Akt
activity (23.5 ± 6% increase in pAkt Ser-473 levels vs. the
IV group; P= 0.03), although this effect was not observed
for pAkt Thr-308 (Figure 3B and 3 C). All the quantifica-
tions of the western blots were normalized with respect to
β-tubulin or β-actin.
In the hippocampus, no changes in total Akt were
observed 54 h after the onset of ischemia (Figure 3D),
although a significant decrease in pAkt Ser-473 was
detected (72 ± 5.1% reduction vs. SV group, P = 0.005;
Figure 3E) and to a lesser extent in pAkt Thr-308
(32 ± 8.5% reduction vs. SV group, P = 0.007; Figure 3F).
A significant recovery in pAkt Ser-473 levels was
induced by post-pMCAO estradiol treatment (IE group;
24 ± 5% increase vs. IV group, P = 0.01) but not in pAkt
Thr-308 (Figure 3E and 3 F). JNK is known to contribute
to apoptotic responses in many cell types. Moreover,
JNK-dependent apoptotic signaling can be blocked by
the activation of survival pathways, including the Akt/
PKB pathway [39]. To study the effect of estradiol treat-
ment on SAPK-JNK activation, we quantified the total
and phosphorylated SAPK-JNK in the ipsilateral cortex
and hippocampus 54 h after inducing pMCAO. In
western blots, no changes in the cortical or hippocampal
levels of phosphorylated SAPK-JNK were evident 54 h
after inducing pMCAO (IV group) when compared
with the SV group (Figure 4B and 4D), a measure of
the activation levels of this kinase. Post-pMCAO estradiol
treatment (IE group) appeared to induce a decrease in
SAPK-JNK phosphorylation that was significant in hippo-
campus but not in cerebral cortex (Figure 4B and 4D).
No changes in the total levels of SAPK-JNK were
observed between experimental groups in either the cor-
tex or hippocampus (Figure 4A and 4B). Post-pMCAO
estradiol treatment alters GSK3 activity in the cerebral
cortex and hippocampus. In many cell types, Akt regu-
lates cell survival by modulating the phosphorylation of
various substrates. The activity of the GSK3α/β is
primarily regulated by Akt-mediated serine phosphorylation
(GSK3α21/β9) and in cortical tissue GSK3 phosphorylation
at residues Ser-21/9 was decreased by pMCAO (53±10%
reduction in IV vs. SV group, P=0.006). Post-pMCAO
estradiol treatment rescued the levels of pGSK3 Ser21/9
(40±9% increase in IE vs. IV group, P=0.01: Figure 5B)
and interestingly, the levels of total GSK3α/β increased
significantly in sham-operated animals after estradiol treat-
ment (42±16% increase in SE vs. SV group, P=0.03:
Figure 5A).
In the ipsilateral hippocampus pMCAO decreased the
levels of pGSK3 Ser-21/9 (36 ± 5.7% decrease in IV vs.
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Figure 2 Post-ischemic estradiol treatment attenuated ‘reactive gliosis’ in the ischemic area. The reactive gliosis induced after 54 h of
pMCAO was measured in coronal brain sections (25 μm thick) by immunohistochemisty for GFAP and Iba1, markers of astrocytes and microglia,
respectively. Representative coronal sections corresponding to the injured area (bregma −1.08) of sham-vehicle (SV), pMCAO-vehicle (IV), and
pMCAO-estradiol (IE) rats are shown. The accompanying bar graph shows GFAP (A) and Iba1 (B) labeling quantified in at least 12 serial coronal
sections from bregma 2.04 and −1.08 with Fiji image processing software, and expressed as the percentage of labeled tissue with respect to the
total area of the photographed sections. The induction of pMCAO induced an increase in the percentage area labeled for GFAP (A) and Iba1 (B)
when determined 54 h after the onset of pMCAO (IV group). Post-pMCAO estradiol treatment (IE group) significantly reduced GFAP (A) and Iba1
(B) labeling to levels comparable with those in the sham-vehicle (SV) animals. The data represent the mean± standard error of the mean (SEM): *
P≤ 0.05, **P≤ 0.005; scale bar = 100 μm.
Pérez-Álvarez et al. Journal of Neuroinflammation 2012, 9:157 Page 6 of 13
http://www.jneuroinflammation.com/content/9/1/157
SV group), albeit to a lesser extent than that observed in
the cortex (Figure 5E). Total hippocampal GSK3α/β also
increased in the SE group (25 ± 6.3% greater vs. SV
group, P = 0.01), yet again to a lesser extent than in the
cortex (Figure 5D). However, in contrast to the effect
observed in the cortex, post-pMCAO estradiol treatment
did not rescue the decrease in pGSK3 Ser21/9 levels
induced by ischemia in the hippocampus (Figure 5E).
GSK3β is a serine-threonine kinase that acts on a
plethora of substrates, including β-catenin and the
microtubule-associated protein tau [46]. β-catenin
stabilization is controlled by the activity of GSK3, among
other kinases [47]. Given the alterations in GSK3α/β
phosphorylation provoked by estradiol treatment, we
analyzed the levels of β-catenin in ischemic rats admi-
nistered estradiol or the vehicle alone. In the cortex,
pMCAO decreased the levels of total β-catenin
(20 ± 7.5% lower in the IV vs. SV group, P = 0.03:
Figure 5C), although this effect appeared to be partially,
if not significantly offset by post-pMCAO estradiol treat-
ment. In the ipsilateral hippocampi there were no
changes in β-catenin levels in any of the experimental
groups (Figure 5F).
Ischemia-induced decreases in pAkt-ser 473 primarily
affect neurons in the ischemic tissue
To determine which cell types were most affected by
pMCAO-induced decrease in the Ser-473 pAkt, we per-
formed dual-immunofluorescence experiments using
specific antibodies against pAkt Ser-473 and GFAP. In
the SV group, cytoplasmic anti-pAkt Ser-473 staining
was predominantly located in neurons, as revealed by
the distinct localization of the GFAP and pAkt Ser-473
signals (Figure 6, SV group). Following pMCAO (IV
group), pAkt Ser-473 levels decreased in GFAP-negative
cells (Figure 6). Post-pMCAO estradiol treatment (IE
group) preferentially rescued pAkt Ser-473 levels in cells
that did not express GFAP (Figure 6).
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Figure 3 Estradiol treatment rescued the decreased levels of phosphorylated Akt Ser-473 induced by ischemia in the cortex and
hippocampus, but not the decrease in Akt Thr-308. Akt activation was inferred in western blots of homogenates from the ipsilateral cerebral
cortex (A, B, C) and hippocampus (D, E, F). The bar graphs show the levels of total Akt (A, D), pAkt Ser-473 (B, E), pAkt Thr-308 (C, F), and
representative blots. The data represent the mean of five independent experiments and β-tubulin or β-actin were used as loading controls. In
both the cortex and hippocampus, pMCAO (IV group) significantly reduced levels of pAKT Ser-473 (B, C) and pAkt Thr-308 (E, F) 54 h after the
onset of ischemia. Post-pMCAO estradiol treatment (IE group) attenuated the decrease in pAkt Ser-473 in the cortex (B) and hippocampus (E),
but had no such effect on pAkt Thr-308 in either region (C, F). No changes in total Akt levels were observed in any of the experimental groups
(A, D). The data are expressed as mean± SEM; * P≤ 0.05; n = 6 rats per group. IE, pMCAO-estradiol; IV, pMCAO-vehicle; SE, Sham-estradiol; SV,
Sham-vehicle.
Pérez-Álvarez et al. Journal of Neuroinflammation 2012, 9:157 Page 7 of 13
http://www.jneuroinflammation.com/content/9/1/157
Discussion
Ischemic stroke is the second leading cause of death
worldwide, yet there are few therapeutic approaches
available to treat this condition and those that exist,
such as thrombolytic tissue plasminogen activator
(tPA), are limited by a narrow therapeutic window [48].
Two murine models are widely used to investigate the
cellular and molecular mechanisms of stroke: transient
and permanent MCAO. While the onset of ischemia
can be precisely defined in animal models, this is rarely
the case in human patients, and indeed, the onset of
symptoms may not coincide with the onset of cerebral
ischemia or they may not be noticed by the patient for
some time [3]. Thus, developing post-ischemia treatments
represents a more realistic and clinically relevant thera-
peutic approach. As such, it is necessary to understand the
pathophysiological events that occur in late stages of
ischemia in order to develop therapeutic strategies that are
effective over a broad time window following ischemia.
Previous studies demonstrated a protective effect of es-
tradiol in pMCAO models when it was administered prior
to the induction of ischemia, mimicking the circulating
physiological levels of the hormone [18,19,49]. However,
few studies to date have investigated the therapeutic effects
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Figure 4 The levels of pSAPK-JNK Thr-183/Tyr-185 were unchanged 54 h after inducing pMCAO. The total SAPK-JNK and pSAPK-JNK Thr-
183/Tyr-185 was measured in western blots of ipsilateral cerebral cortex (A, B) and hippocampus (C, D) homogenates. The bar graphs show total
levels of SAPK-JNK (A, C) and pSAPK-JNK Thr-183/Tyr-185 (B, D), and representative blots. The data represent the mean of three to five
independent experiments and β-tubulin or β-actin were used as loading controls. In both the cerebral cortex (A, B) or hippocampus (C, D),
pMCAO had no major effect on the levels of total SAPK-JNK (A, C) or pSAPK-JNK Thr-183/Tyr-185 (B, D). Post-pMCAO estradiol treatment
produced a slight decrease in pSAPK-JNK Thr-183/Tyr-185 levels in the cerebral cortex (B), and a significantly decreased in the levels of pSAPK-JNK
in the hippocampus, as compared with the SV group (D). Data are expressed as the mean± SEM (n = 6 rats per group). IE, pMCAO-estradiol; IV,
pMCAO-vehicle; SE, Sham-estradiol; SV, Sham-vehicle.
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of physiological estradiol treatment after the induction of
ischemia. Our findings describe a potential mechanism
of estrogen-induced neuroprotection in late stages of
pMCAO in male rats, suggesting a significant clinical
potential of estradiol to treat ischemic stroke.
Administration of estradiol (0.04 mg/kg) 6, 24, and 48 h
post-pMCAO decreased the reactive gliosis 54 h post-
pMCAO, as witnessed by the expression of GFAP and
Iba1, an effect that was more pronounced in the ipsilateral
cortex than the ipsilateral hippocampus. Differential
down-regulation of the PI3K/Akt/GSK3/β-catenin path-
way was observed in the cortex and hippocampus in the
late stages of cerebral ischemia, while there were no
changes in JNK phosphorylation following pMCAO in ei-
ther region. Post-ischemic treatment with three doses of
estradiol, beginning 6 h after the onset of pMCAO, par-
tially recovered the activity of the PI3K/Akt/GSK3/β-cate-
nin pathway, although this effect was more pronounced in
the cerebral cortex (the region most affected by ischemia
in this model) than in the hippocampus (secondary death
cell area). Finally, the substantial decrease in pAkt (Ser-
473) levels after pMCAO predominantly affected GFAP-
negative cells and attending to their morphology and size,
mostly neurons in the ischemic area.
Like many other neurodegenerative disorders, the re-
active gliosis associated with ischemic stroke involves
both astrocytes and microglia [44,50,51]. This response
can vary depending on the severity and extent of brain
damage, and it involves both positive elements, such as
neurotrophins and anti-inflammatory components, and
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Figure 5 Post-ischemic estradiol treatment restores pGSK3Ser21/9 levels in the cerebral cortex but not the hippocampus. Levels of
phosphorylated GSK3 and total β-catenin (a substrate of GSK3) were measured in western blots of homogenates from the ipsilateral cerebral
cortex (A, B, C) and hippocampus (D, E, F). The bar graphs show the total GSK3 (A, D), the pGSK3Ser21/9 (B, E), and the total β-catenin (C, F), as
well as representative blots. The data represent the mean of three to five independent experiments, using β-tubulin or β-actin as loading
controls. In the ipsilateral cortex (B) and hippocampus (E), pMCAO (IV group) significantly reduced the pGSK3Ser21/9 levels and total β-catenin
levels 54 h after the onset of ischemia when compared with the SV group. Post-pMCAO estradiol treatment attenuated the decrease in
pGSK3Ser21/9 (B) and β-catenin (C) levels in the cerebral cortex, but it had no effect on pGSK3Ser21/9 levels in the hippocampus (E). No changes
in total β-catenin levels were observed in the hippocampus in any experimental group (F). Total GSK3 levels increased significantly following
estradiol treatment in sham operated animals (SE), both in the cortex (A) and hippocampus (C), as compared with the corresponding control (SV)
group. The data are expressed as mean± SEM: * P≤ 0.05; n = 6 rats per group. IE, pMCAO-estradiol; IV, pMCAO-vehicle; SE, Sham-estradiol; SV,
Sham-vehicle.
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‘negative elements’, including proteoglycans or compo-
nents of myelin [39,51-56]. It is therefore important to
consider both these aspects of the reactive glial response
when developing therapies for ischemic stroke. A strong
correlation between the size of the infarct area and the
accumulation of microglia has been described previously
in the tMCAO model [39]. However, have been
describes that estrogens can either decreased [57,58], or
even increased [59,60] the number of reactive astrocytes
in some models of brain injury. The molecular causes
for these differences are still unknown. Some authors
postulate that this may represent the relative role of ERα
and ERβ on the control of the neural inflammatory
response in vivo, and it would depend on both type of
injury and/or the CNS region [57]. This is, to our
knowledge, the first study to analyze the effect of estradiol
on the accumulation of reactive glia (both astrocytes and
microglia) during cerebral ischemia processes. Indeed,
post-pMCAO treatment with estradiol significantly
decreased in GFAP and Iba1 immunostaining in the ische-
mic area (cortex), reducing their levels to those seen in
the control animals (SV). The reduction in reactive gliosis
following estradiol treatment demonstrates an attenuation
of ischemic damage, although the mechanisms underlying
this effect are poorly understood. Estradiol treatment
appears to up-regulate anti-inflammatory genes in the
cortex, primarily via ER alpha, and it up-regulates the
synthesis of ER alpha [61]. Moreover, GSK3β inhibitors
[62] attenuate the enhanced mRNA expression of proin-
flammatory mediators induced by ischemia in a pMCAO
model, including iNOS, TNF-α and IL-1β typically released
by activated glial cells.
The effect of estradiol may also be partially mediated
by complementary effects in neurons. Indeed, multiple
mechanisms may underlie the effects of neuroprotective
agents, combining the inhibition of neuronal cell death
and combating the detrimental effects of inflammation
in the treatment of stroke [63]. It is widely accepted that
cell death in the ischemic core is mainly triggered by ne-
crosis, due to restricted blood flow, while that occurring
in the penumbra is predominantly mediated by apop-
tosis [4,64,65]. As apoptosis is a reversible process, re-
search has focused on the apoptotic pathways involved
in neuronal death after MCAO, with a view to identify-
ing important therapeutic targets. Down-regulation of
the PI3K/Akt pathway, a crucial regulator of neuronal
cell survival [66], has been described up to 24 h after
pMCAO induction [31,67-69]. This pathway was down-
regulated 54 h after the onset of pMCAO in the two
tissues differentially affected by ischemia, the cerebral
cortex (corresponding to the most affected region) and
the ipsilateral hippocampus. Indeed, in both the ipsilateral
cortex and hippocampus pMCAO induced a decrease in
the levels of pAkt Ser-473 and to a lesser extent pAkt
Thr-308, without significantly affecting total Akt levels,
suggesting a loss of Akt activity. Phosphorylation of both
Thr-308 and Ser-473 residues is required for maximum
activation of Akt [70], and it is mediated by distinct
kinases: phosphoinositide-dependent kinase 1 (PDK1) and
mTORC2, respectively [71,72]. The mechanism of acti-
vation of mTORC2 has not been fully characterized,
although its direct role in Ser473 phosphorylation has been
clearly demonstrated [73]. Our findings are consistent with
previous reports describing a decrease in p-PDK1
(Ser241) and pAkt (Ser473) levels in the ipsilateral cortex
when compared with the contralateral counterpart 24 h
after of the induction of pMCAO [49]. Furthermore, we
found that post-pMCAO estradiol treatment led to partial
recovery of pAkt Ser-473 levels in both ipsilateral regions
(cortex and hippocampus), without affecting pAkt Thr-308
SV IV IE
SV IV IE
pAKT(Ser473)
C
C
GFAP
Figure 6 The decrease in pAkt Ser-473 levels induced by ischemia and its subsequent rescue by estradiol treatment primarily occurs in
neurons within the ischemic area. Representative coronal brain sections corresponding to bregma −1.08 of control (SV) and pMCAO (IV) rats,
and from estradiol-treated pMCAO animals (IE group). Images show the ipsilateral ischemic cortex double stained for GFAP (red) and pAkt Ser-
473 (green). pMCAO (IV group) resulted in a decrease in the intensity of pAktSer-473 staining and an increase in GFAP staining intensity 54 h after
the induction of ischemia, when compared with the control (IV) group. Post-pMCAO estradiol treatment rescued this decrease in pAkt Ser-473
levels and decreased GFAP staining, resulting in levels similar to those of the control (SV) group. The pAkt Ser-473 immunoreactivity (green) did
not co-localize with that of GFAP (red). Representative cells exhibiting pAkt Ser-473-positive cytoplasmic labeling are indicated in SV and IE panels
(arrows). The size and morphology of these cells strongly suggests they are neurons. Scale bar = 25 μm.
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levels. These results suggest that estradiol regulates
mTORC2 activity without substantially altering PDK-1
activity, although the underlying mechanism remains
unclear. Alternatively, pAkt Ser-473 and pAkt Thr-308
may be differentially affected by the activation of specific
phosphatases.
The decrease in pAkt Ser-473 levels in pMCAO ani-
mals (IV group) was not restricted to GFAP-positive
cells but rather, it occurred predominantly in neurons.
Moreover, post-pMCAO estradiol treatment reversed
this effect, restoring the pAkt Ser-473 levels in these
cells. These findings suggest that the effect of estradiol is
not limited to the attenuation of activated gliosis in glial
cells but also, that it affects the activity of the PI3K/Akt
survival pathway in neurons. Indeed, we recently
reported that estradiol may activate or cooperate with
PI3K to phosphorylate and activate Akt [23,74]. The de-
crease in Akt phosphorylation at both Ser473 and
Thr308 residues suggested a reduction in Akt activity fol-
lowing pMCAO and thus, we analyzed the phosphorylation
of GSK3α/β, a key downstream target of Akt. Phos-
phorylation of GSK3α/β by Akt at Ser-21/9 inactivates
its kinase activity and may regulate cellular apoptosis
[75]. After 54 h of pMCAO, the decrease in pGSK3
Ser-21/9 detected in the cortex, and to a lesser extent
in the hippocampus, is consistent with the observed
reduction in Akt activity and it was correlated with an
increase in GSK3 activity that may promote or mediate
cell death [28,76,77]. Our data demonstrate that the
pMCAO-induced decrease in cortical pGSK3 Ser-21/9
is rescued by estradiol treatment, virtually reverting to
the levels seen in vehicle-treated animals (SV). Based
on this finding, we propose two possible mechanisms
of action by which estradiol may reduce reactive gliosis
after pMCAO, through: (1) the direct inhibition of
GSK3 in glial cells that subsequently alters the glial
response; and (2) the direct modulation of Akt, and
hence the GSK3 activity in neurons, resulting in a
reduced pro-inflammatory response [62]. Analysis of
the ipsilateral hippocampi revealed no recovery of
pGSK3 Ser-21/9 levels following estradiol treatment,
suggesting that the activity of estradiol depends on the
specific neurons and/or glial receptors differentially
expressed in the cortex and hippocampus. Further
studies will be aimed at investigating this hypothesis.
The activation of MAPK signaling pathways during
ischemia plays an important role in apoptosis and
inflammation. The inflammatory response increases the
damage area, a process that is particularly pronounced
during reperfusion [56]. In animal models of stroke
several inhibitors of the JNK pathway have protective
effects [39,56]. In our pMCAO model (without reperfu-
sion), we detected no changes in total JNK or in the
phosphorylation status of this enzyme at Thr183/Tyr185
residues after 54 h of pMCAO. Hence, the JNK signaling
pathway does not appear to play a significant role in
pMCAO, at least at 54 h after ischemia induction.
Further studies will be necessary to determine whether
the neuroprotective effect of estradiol is receptor-
specific, permitting the development of more selective
treatments that enhance neuroprotection while avoiding
some of the negative effects in non-neural cells.
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